阿司匹林一级预防心血管疾病:争议中带来的新思考

Primary Prevention of Aspirin for Cardiovascular Disease:new ideas in dispute

阿司匹林一级预防心血管疾病的争议由来已久,2014年FDA否决拜耳公司将阿司匹林适应证扩大至一级预防将阿司匹林再次推到风口浪尖,一级预防究竟是科学用药还是过度治疗仍无定论。回顾阿司匹林的循证医学证据,笔者仍然坚信通过对获益和风险的有效评估,精细化管理适应人群将促使阿司匹林在一级预防上的路越走越远,未来的临床应用前景也会越来越大。本文着力在现有循证医学证据中寻找答案,为阿司匹林一级预防心血管疾病的临床干预带来新的思考。

There was a dispute of aspirin for primary prevention of cardiovascular disease for a long time. In 2014, FDA rejected that Bayer modified the description in order to use aspirin for primary prevention of cardiovascular disease. So, is primary prevention of aspirin over-treatment medicine or scientific medicine？ The answer remained unknown. From evidence-based medicine of aspirin, through effective assessment of the benefits and risks, we still convinced that a potential clinical application of aspirin would appear in the future. We focused on looking for the truth and brought new ideas to primary prevention of aspirin in clinical medicine.